Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada
Reason given: Recruitment
Key facts
- Where
- Montreal, CanadaSee the site
Where in Canada
- PROxy Network, an initiative of PeriPharm inc.Montreal, CanadaNo longer taking part
Trial details
- Who runs it
- PeriPharm
- Trial code
- NCT07035067
- Record updated
- 7 April 2026
- Original description
Filling the gap in Canadian evidence on the burden of PROC on QoL is essential. It will help better understand the impact of PROC on multiple aspects of the lives of patients and their caregivers and the real-life hurdles faced by PROC patients and their caregivers. The outputs of this study will help better understand the hurdles and challenges they face and the significant unmet medical need.Read full original descriptionShow less
Filling the gap in Canadian evidence on the burden of PROC on QoL is essential. It will help better understand the impact of PROC on multiple aspects of the lives of patients and their caregivers and the real-life hurdles faced by PROC patients and their caregivers. The outputs of this study will help better understand the hurdles and challenges they face and the significant unmet medical need.
Patient Inclusion Criteria; ≥18 years old; Patients with PROC who received >1 prior line of therapy identified through a screening survey. PROC will be defined as recurrence less than 6 months after last platinum chemotherapy (i.e. carboplatin or cisplatin); Ability to read and understand French or English; Signature of ICF; Patients Exclusion Criteria; Patients with PSOC, defined as those who:; Have not progressed within less than 6 months after completion of platinum-based chemotherapy or; Are still on platinum chemotherapy or; Receive maintenance therapy; Patients with platinum-refractory ovarian cancer, defined as not responding or disease progressing during therapy or within three months after the last dose; Caregivers Inclusion Criteria:; ≥18 years old; Current caregiver of a patient with PROC (see definition to be used above) who received >1 prior line of therapy identified through a screening survey; Ability to read and understand French or English; Signature of ICF; Caregivers Exclusion Criteria:; Caregivers of patients with PSOC (see definition above); Caregivers of PROC patients who have passed away; Caregivers of platinum-refractory patients (see definition above).